Clinical Trial Update: Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly) [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluates the safety and efficacy of Zemplar (paricalcitol) capsules given three times weekly in adults with chronic kidney disease to reduce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

Sponsor: Abbott | Conditions: Renal Insufficiency, Chronic | Phase 3 | Status: COMPLETED